PURPOSE: To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in human breast tumor progression. EXPERIMENTAL DESIGN: We did immunohistochemical analyses of CTSK and CXCL14 expression in normal breast tissue, biopsy sites, benign lesions, ductal carcinoma in situ, and invasive breast tumors of different stages. Expression patterns were related to histopathologic characteristics of the tumors and clinical outcome. The effect of CTSK+ breast stromal fibroblasts on CTSK- breast cancer cells was assessed in coculture. RESULTS: Epithelial expression of CTSK was rarely detected in any of the tissue samples analyzed, whereas CXCL14-positive epithelial cells were found in all tissue types. The expression of CXCL14 was not associated with any tumor or patient characteristics analyzed. Stromal CTSK expression was significantly higher in invasive compared with in situ carcinomas, and in one of the two data sets analyzed, it correlated with higher tumor stage. Among all samples examined, the highest stromal CTSK levels were detected in biopsy sites. Neither epithelial nor stromal expression of CTSK was significantly associated with recurrence-free or overall survival. Coculture of CTSK+ fibroblasts enhanced the invasion of CTSK- breast tumor epithelial cells and this was blocked by CTSK inhibitors. CONCLUSIONS: CTSK may function as a paracrine factor in breast tumorigenesis. CTSK+ fibroblasts may play a role in tumor progression by promoting the invasiveness of tumor epithelial cells. The possibility that CTSK inhibitors may have a clinical role in decreasing the risk of tumor progression merits further investigation.
PURPOSE: To evaluate the expression of cathepsin K (CTSK) and CXCL14 in stromal and epithelial cells in humanbreast tumor progression. EXPERIMENTAL DESIGN: We did immunohistochemical analyses of CTSK and CXCL14 expression in normal breast tissue, biopsy sites, benign lesions, ductal carcinoma in situ, and invasive breast tumors of different stages. Expression patterns were related to histopathologic characteristics of the tumors and clinical outcome. The effect of CTSK+ breast stromal fibroblasts on CTSK- breast cancer cells was assessed in coculture. RESULTS: Epithelial expression of CTSK was rarely detected in any of the tissue samples analyzed, whereas CXCL14-positive epithelial cells were found in all tissue types. The expression of CXCL14 was not associated with any tumor or patient characteristics analyzed. Stromal CTSK expression was significantly higher in invasive compared with in situ carcinomas, and in one of the two data sets analyzed, it correlated with higher tumor stage. Among all samples examined, the highest stromal CTSK levels were detected in biopsy sites. Neither epithelial nor stromal expression of CTSK was significantly associated with recurrence-free or overall survival. Coculture of CTSK+ fibroblasts enhanced the invasion of CTSK- breast tumor epithelial cells and this was blocked by CTSK inhibitors. CONCLUSIONS:CTSK may function as a paracrine factor in breast tumorigenesis. CTSK+ fibroblasts may play a role in tumor progression by promoting the invasiveness of tumor epithelial cells. The possibility that CTSK inhibitors may have a clinical role in decreasing the risk of tumor progression merits further investigation.
Authors: Katherine M Bell-McGuinn; Alfred L Garfall; Matthew Bogyo; Douglas Hanahan; Johanna A Joyce Journal: Cancer Res Date: 2007-08-01 Impact factor: 12.701
Authors: Olga Vasiljeva; Thomas Reinheckel; Christoph Peters; Dusan Turk; Vito Turk; Boris Turk Journal: Curr Pharm Des Date: 2007 Impact factor: 3.116
Authors: Simone Meuter; Patrick Schaerli; Regula Stuber Roos; Oliver Brandau; Michael R Bösl; Ulrich H von Andrian; Bernhard Moser Journal: Mol Cell Biol Date: 2006-11-27 Impact factor: 4.272
Authors: Céline Le Gall; Akeila Bellahcène; Edith Bonnelye; Jürg A Gasser; Vincent Castronovo; Jonathan Green; Johann Zimmermann; Philippe Clézardin Journal: Cancer Res Date: 2007-10-15 Impact factor: 12.701
Authors: Michail Shipitsin; Lauren L Campbell; Pedram Argani; Stanislawa Weremowicz; Noga Bloushtain-Qimron; Jun Yao; Tatiana Nikolskaya; Tatiana Serebryiskaya; Rameen Beroukhim; Min Hu; Marc K Halushka; Saraswati Sukumar; Leroy M Parker; Karen S Anderson; Lyndsay N Harris; Judy E Garber; Andrea L Richardson; Stuart J Schnitt; Yuri Nikolsky; Rebecca S Gelman; Kornelia Polyak Journal: Cancer Cell Date: 2007-03 Impact factor: 31.743
Authors: Ubaldo E Martinez-Outschoorn; Casey Trimmer; Zhao Lin; Diana Whitaker-Menezes; Barbara Chiavarina; Jie Zhou; Chengwang Wang; Stephanos Pavlides; Maria P Martinez-Cantarin; Franco Capozza; Agnieszka K Witkiewicz; Neal Flomenberg; Anthony Howell; Richard G Pestell; Jaime Caro; Michael P Lisanti; Federica Sotgia Journal: Cell Cycle Date: 2010-09-09 Impact factor: 4.534
Authors: Min Hu; Guillermo Peluffo; Haiyan Chen; Rebecca Gelman; Stuart Schnitt; Kornelia Polyak Journal: Proc Natl Acad Sci U S A Date: 2009-02-13 Impact factor: 11.205
Authors: Martin Augsten; Christina Hägglöf; Eleonor Olsson; Claudia Stolz; Panagiotis Tsagozis; Tetyana Levchenko; Mitchell J Frederick; Ake Borg; Patrick Micke; Lars Egevad; Arne Ostman Journal: Proc Natl Acad Sci U S A Date: 2009-02-13 Impact factor: 11.205
Authors: Izabela Podgorski; Bruce E Linebaugh; Jennifer E Koblinski; Deborah L Rudy; Mackenzie K Herroon; Mary B Olive; Bonnie F Sloane Journal: Am J Pathol Date: 2009-08-21 Impact factor: 4.307
Authors: Gang Zheng; Guido Martignoni; Cristina Antonescu; Elizabeth Montgomery; Charles Eberhart; George Netto; Janis Taube; William Westra; Jonathan I Epstein; Tamara Lotan; Anirban Maitra; Edward Gabrielson; Michael Torbenson; Christine Iacobuzio-Donahue; Angelo Demarzo; Ie Ming Shih; Peter Illei; T C Wu; Pedram Argani Journal: Am J Clin Pathol Date: 2013-02 Impact factor: 2.493
Authors: Andriy Marusyk; Doris P Tabassum; Michalina Janiszewska; Andrew E Place; Anne Trinh; Andrii I Rozhok; Saumyadipta Pyne; Jennifer L Guerriero; Shaokun Shu; Muhammad Ekram; Alexander Ishkin; Daniel P Cahill; Yuri Nikolsky; Timothy A Chan; Mothaffar F Rimawi; Susan Hilsenbeck; Rachel Schiff; Kent C Osborne; Antony Letai; Kornelia Polyak Journal: Cancer Res Date: 2016-09-26 Impact factor: 12.701